List view / Grid view

U.S. Food and Drug Administration (FDA)

 

whitepaper

Whitepaper: Possible Mechanism of Low Endotoxin Recovery

26 October 2016 | By

Since the risks of LER relate to the reversible biological activity change of endotoxin, it is worth reviewing previous papers on the aggregation of purified lipopolysaccharide (LPS) and its biological activity. The purpose of this article is to discuss the potency change of endotoxin in the LER by reviewing previous…